SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sonus Pharma (SNUS) ? Opinions
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who wrote (258)3/12/1998 11:25:00 AM
From: (no name provided)  Read Replies (1) of 384
 
From MB 10Q:

" In November and December 1997, the PTO issued office actions in
connection with the Company's patent reexamination petitions filed against Sonus
and Nycomed, respectively. The PTO office actions reject all relevant claims of
the patents owned by Sonus and Nycomed involved in the MBI Case and the Sonus
Case, based on prior art not previously disclosed to the PTO by Sonus and
Nycomed during prosecution of their patent applications. If maintained through
further proceedings before the patent examiner and on any appeal, the PTO
rejections will invalidate the patents which Sonus and Nycomed are attempting to
assert against the Company and Mallinckrodt to block the manufacture and sale of
OPTISON(TM). "

Has SNUS ever disclosed this?

Kafka666
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News